IndiaMedToday’s Post

The pharmaceutical industry is undergoing a remarkable transformation, marked by technological innovation and evolving regulatory landscapes. These changes are setting the stage for the future of healthcare, ensuring that new treatments are safe, effective, and accessible. Discover more insights in the full article: https://lnkd.in/gidvuHCA #PharmaIndustry #Innovation #FutureOfHealthcare

The Global Pharma Contract Commercialization (CCO) Market is anticipated to grow at a CAGR of 5% by 2029. This growth is driven by several factors including increasing R&D costs, declining pharmaceutical sales, enhanced regulatory scrutiny, and the growing demand for market access, Real-World Evidence (#RWE), Health Economics and Outcomes Research (#HEOR), pricing and reimbursement, regulatory and compliance services, and challenges associated with complex therapies. https://lnkd.in/e9rrZxW3

In 2022, the pharmaceutical manufacturer Biogen paid $900 million to settle a lawsuit for paying kickbacks to persuade doctors to prescribe its drugs for multiple sclerosis. Biogen did not admit wrongdoing, but the suit asserted that the company used consulting fees and honorariums for participation in speakers programs and advisory boards to induce the doctors to prescribe the drugs. Though this lawsuit is another example of a well known industry strategy, the extent of the program was dramatic. In BMJ, Joseph Ross, Reshma Ramachandran, and I give details on the Biogen case and draw lessons from this case and several others for doctors' engagement with industry through consulting, speakers programs, and advisory board service. You can read more here (please DM me if stuck behind the paywall): https://lnkd.in/ehb_pWvy

"Even though there have been several purpose-driven pharmaceutical sector assessments, such as the one conducted for the policy review, it took about seven years since the Ministry of Health (MOH) did holistic pharmaceutical system assessments". This statement was from last week's discussion between the ARC team and the MOH at the Pharmaceuticals and Medical Devises Lead Executive Office (PMGLEO). The meeting further emphasized the importance of national pharmaceutical sector assessments, which help diagnose problems, plan major reforms and interventions, monitor progress, and compare one system's performance with that of another. MOH Ethiopia is at the last stage of finalizing the pharmaceutical Policy and has started developing the national costed roadmap in anticipation of the draft plan's approval soon. The old Policy was revised to consider global dynamics, pandemic conditions, economic activities, and changing digitalization affecting pharmaceuticals and medical devices. With all this in mind, the initial meeting proposed the need for a national comprehensive pharmaceutical and medical device sector assessment, which includes manufacturing, regulatory, supply chain, traditional medicines, and research and development within the scope of pharmaceuticals and medical devices. MOH-PMDLEO wanted partners to collaborate on this activity, and ARC would work to materialize the plan as soon as possible before the finalization of the roadmap. The picture below was taken during the meeting- Mr Regasa Bayissa- Lead executive officer of PMD LEO (Middle) Mr Teshome Dires Senior Advisor- State Minister office MOH- (far Right) Mr Alemayehu Lemma Wolde- ARC country lead- (Right) Mr Feyisa Wakayo- ARC Technical Advisor -PMD-LEO (Left) Mr Birhanu Tadesse- Team Lead of Supply Chain team- PMDLEO (far Left) Africa Resource Centre; Ibnou khadim Diaw; BONFACE FUNDAFUNDA Regasa Bayisa, Teshome Dires; Berhanu TadesseFeyissa Safawo WakeyoNatty S. KokoloHany Abdallah#

Elisa Lorenzo Sanchez shares the latest update from Spain regarding the launch of the Pharmaceutical Industry Strategy 2024-2028. The strategy provides a comprehensive roadmap designed to strengthen the sector, ensuring access to quality medicines, fostering innovation, and maintaining the sustainability of the healthcare system. In this article, Elisa outlines the critical initiatives set to take place. #PharmaceuticalIndustry #Innovation #Healthcare

In the latest edition of the "Welcome to the Future" series, Marcos Cortes, Managing Director of A&M’s Corporate Transactions Group, examines the implications of the Inflation Reduction Act (IRA) on pharmaceutical research and development. As the industry allocates a substantial share of revenue to R&D, adjustments in drug pricing are likely to affect upcoming R&D budgets and strategies. Check out Marcos's insights on Medicare drug negotiation under the IRA and its potential effects on the pharmaceutical sector and future innovation investments. https://okt.to/KSaqVF #InflationReductionAct #CorporateTransactionsGroup

🌟 EUCOPE Welcomes New Commissioners to Propel Pharma Innovation in Europe! 🌟 In a pivotal moment for the pharmaceutical landscape, EUCOPE extends its congratulations to the newly appointed European Commissioners. Their leadership is essential for enhancing innovation and competitiveness within the EU's pharmaceutical sector. 🔑 Key Highlights: - Strengthened collaboration among small and mid-sized firms is set to drive significant innovation. - The implementation of the EU Rare Disease Framework will streamline orphan drug development. - Continued investment in research infrastructure is critical for maintaining Europe’s leadership in medical advancements. As emphasized by Alexander Natz, Secretary General of EUCOPE, a robust pharmaceutical ecosystem is vital for ensuring timely access to cutting-edge treatments across Europe. 📈 By prioritizing an innovation-centric approach, we can spur economic growth while delivering superior health outcomes. EUCOPE remains committed to partnering with the new Commission as we tackle future challenges together! 👉 Click on the link for more insights! #EUCOPEStrategy #HealthcareLeadership #MedicalAdvancements #OrphanDrugs #Pharma #PharmaInnovation #RegulatoryAgencies #MarketAccess #MarketAccessToday

We need pharmaceuticals controlled by state regulations and out of the lobbies' grip in Washington DC. Shifting control of pharmaceuticals from federal oversight to state regulation and reducing lobbyist influence in Washington could indeed address many issues, such as drug pricing and access. The influence of pharmaceutical lobbyists in shaping policy has long been criticized, as these companies have often prioritized profits over public health, resulting in skyrocketing drug prices and limited access to necessary medications for many Americans. A more effective economic development authority that employs locals with community first and lobbyists not invited and draining money for middle man money changers. Moving to a state-controlled regulatory framework for pharmaceuticals could mean that states set their standards for drug pricing, approval, and distribution. This decentralization might encourage competition, drive down costs, and foster innovation as states try different models. Additionally, it could increase transparency by allowing for more localized and responsive systems, potentially holding pharmaceutical companies more accountable.

🚨 Germany Enforces Stricter Recruitment Standards for Pharma Studies! 🇩🇪💊 In a significant move to enhance the relevance of clinical trial data, Germany has enacted the Medical Research Act, mandating that pharmaceutical companies adhere to stricter recruitment criteria for their studies. 🔑 Key Highlights: - Ensures studies reflect the German patient population - Increases relevance of clinical trial data for local markets - May elevate administrative burdens on pharmaceutical firms - Aims to improve integration of new drugs into Germany's healthcare system Starting January 2025, companies must demonstrate that at least 5% of study participants are sourced from German test sites. The Gemeinsame Bundesausschuss (G-BA) will oversee compliance and evaluation processes. Pharmaceutical firms are urged to adapt their recruitment strategies now! This proactive approach will not only align with regulatory expectations but also enhance the credibility and applicability of research outcomes. For more insights on these new regulations and what they mean for your organization, click on the link! 🏥📊 #ClinicalTrials #Germany #HealthcareInnovation #MedicalResearch #Pharma #PricingandReimbursement #RegulatoryAgencies #MarketAccess #MarketAccessToday

The ongoing evolution of the pharmaceutical industry, aimed at propelling the next generation of medicines requires the close collaboration with regulators, emphasizing innovation, partnership, and a continued dedication to addressing patient needs. This transformation holds the potential to guide significant advancements in the development and delivery of medicines, leading to improved healthcare outcomes for patients. The Regulatory, Compliance and Quality (RCQ) track planned for the 2024 ISPE Annual Meeting & Expo, taking place 13-16 October, in Orlando, Florida, USA. will feature industry and regulatory experts in a variety of topic areas. Read more in this iSpeak article by program committee members, Ciby J. Abraham, Ph.D., David Churchward, Connie Langer, and Silas Tamufor: https://hubs.ly/Q02K-41P0 #ISPE #pharma #pharmaregulatory #pharmaconference #biotech #pharmaceuticalmanufacturing